1. Scrip

Merck's Anacetrapib Survives Futility Exam, But Will It Pass Final Test?

 
• By Mandy Jackson

Merck & Co. Inc. has been fairly tight-lipped about its cholesteryl ester transfer protein (CETP) inhibitor anacetrapib for hypercholesterolemia while the 30,000-patient Phase III REVEAL clinical trial is ongoing, but the company said on Nov. 13 that the drug passed a recent futility test.

Merck & Co. Inc. has been fairly tight-lipped about its cholesteryl ester transfer protein (CETP) inhibitor anacetrapib for hypercholesterolemia while the 30,000-patient Phase III REVEAL clinical trial is ongoing, but the company said on Nov. 13 that the drug passed a recent futility test.

The REVEAL data monitoring committee (DMC) conducted a planned review of unblinded safety and efficacy data and said the trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?